Marks decries lack of transparency in FDA's revamped COVID vaccine policy
Regulatory NewsEmily Hayes
Biologics/ biosimilars/ vaccinesCoronavirus/COVID-19Product LifecycleRegulatory Intelligence/PolicyUnited StatesRegulatory NewsEmily HayesBiologics/ biosimilars/ vaccinesCoronavirus/COVID-19Product LifecycleRegulatory Intelligence/PolicyUnited States